Results 151 to 160 of about 35,234 (228)

Therapeutic advances in Marburg virus disease: from experimental treatments to vaccine development. [PDF]

Ann Med Surg (Lond)
Paison F, Ubuzima P, Nshimiyimana E, Habumugisha J, Atukunda S, Ayebare F, Munyurangabo G, Amikoro B, Su B.   +8 more
europepmc   +1 more source

Identification of potential VP40 inhibitor of Marburg virus through molecular docking, pharmacokinetic analysis and molecular dynamics simulation. [PDF]

Sci Rep
Das R, Bhattarai A, Tamang B, Thakur N.
europepmc   +1 more source

Kinetics of hematological and biochemical biomarkers are key tools for monitoring disease progression in Marburg virus-infected patients in Rwanda. [PDF]

Sci Rep
Mugisha JC, Kayigi E, Gahamanyi N, Uwayo HD, Umwanankabandi F, Gashema P, Rwagasore E, Turatsinze D, Nkeshimana M, Gashegu M, Ntagwabira E, Makayoto L, Ngabonziza JCS, Mukagatare I, Tuyishime A, Rujeni N, Mutesa L, Seruyange E, Musafiri S, Twagirumugabe T, Harelimana JD, Muvunyi CM.   +21 more
europepmc   +1 more source

Genomic and transmission dynamics of the 2024 Marburg virus outbreak in Rwanda. [PDF]

Nat Med
Butera Y, Mutesa L, Parker E, Muvunyi R, Umumararungu E, Ayitewala A, Musabyimana JP, Olono A, Sesonga P, Ogunsanya O, Kabalisa E, Adedokun O, Gahima N, Irankunda L, Mutezemariya C, Niyonkuru R, Uwituze A, Uwizera I, Kagame J, Umugwaneza A, Rwabuhihi J, Umwanankabandi F, Mbonitegeka V, Ntagwabira E, Kayigi E, Izuwayo G, Murenzi H, Mukankwiro T, Tuyiringire N, Uwimana JMV, Gasengayire A, Sindayiheba R, Onyeugo GU, Aragaw M, Gitundu L, Bigirimana R, Fallah M, Ejikeme A, Sembuche S, Kabanda A, Mugisha JC, Francis EES, Gashema P, Ndayisenga J, Rugamba A, Kanyabwisha F, Murenzi G, Happi A, Ngabonziza JCS, Gashegu M, Ahmed A, Bigirimana N, Rwagasore E, Semakula M, Rwabihama JP, Musanabaganwa C, Seruyange E, Nkeshimana M, Twagirumugabe T, Turatsinze D, Remera E, Gahamanyi N, Tessema SK, Mukagatare I, Nsanzimana S, Happi C, Muvunyi CM.   +66 more
europepmc   +1 more source

Process Intensification for Recombinant Marburg Virus Glycoprotein Production Using <i>Drosophila</i> S2 Cells. [PDF]

Eng Life Sci
Göbel S, Mayerlen L, Eiser IY, Fichtmueller L, Clements D, Reichl U, Genzel Y, Lehrer A.   +7 more
europepmc   +1 more source

Thirteen-Year Sequelae of Marburg Virus Disease Survival: Persistent Cardiometabolic, Immunometabolic, and Haematological Alterations in the Absence of Psychological Morbidity. [PDF]

Pathogens
Serwanga J, Kaweesa RE, Ssebwana JK, Odoch G, Wayesu RR, Ntabadde AD, Mukisa D, Ejou P, FiloStudy Team, Lutwama JJ, Kaleebu P.   +10 more
europepmc   +1 more source

Marburg Virus Disease: Epidemiology, Immune Responses, and Innovations in Vaccination and Treatment for Enhanced Public Health Strategies. [PDF]

Pathogens
Dzinamarira T, Muvunyi CM.
europepmc   +1 more source

Marburg virus glycoprotein mRNA vaccine is more protective than a virus-like particle-forming mRNA vaccine. [PDF]

J Clin Invest
Subramani C, Meyer M, Hyde MA, Comeaux ME, Hao H, Crowe JE, Popov VL, Thaker H, Himansu S, Carfi A, Bukreyev A.   +10 more
europepmc   +1 more source

Conservation of structure and immune antagonist functions of filoviral VP35 homologs present in microbat genomes [PDF]

, 2018
Amarasinghe, Gaya K, Basler, Christopher F, Edwards, Megan R, Ginell, Garrett M, Keefe, Lisa J, Kollner, Bernd, Leung, Daisy W, Liu, Hejun, Luthra, Priya, Ramanan, Parmeshwaran, Shabman, Reed S, Taylor, Derek J   +11 more
core   +1 more source